euro-obesity-euro-vaccines-2018-tracks

allied

academies

OBESITY AND WEIGHT MANAGEMENT

VACCINES AND IMMUNOLOGY

International Conference on

J u n e 2 8 - 2 9 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s

Asian Journal of Biomedical and Pharmaceutical Sciences

Volume 8

ISSN:

2249-622X

Page 16

Note:

Joint Event on

he vaccine segment is anticipated to be one of the fastest growing one

of the healthcare industry and several leading firms have stepped up

vaccine investments in recent years. Unlike therapeutic agents, vaccines are

administered to healthy individuals only once or very infrequently during a

life time. Vaccines generate well-documented positive externalities, yet their

poor awareness and acceptability among vaccine end-users may contribute to

resurgence of transmissible diseases and consequently trigger governmental

interventions such as mandating vaccination. In addition to technical and

clinical development per the highest quality standards, bringing new vaccines

to market requires carefully orchestrated programs targeting the multiple types

of stakeholders along the entire value chain and addressing their respective

purchasing behavioral drivers. Against a backdrop of anti-vaccination buzz

and vaccine fatigue, successful global launch and sustainable usage of a

vaccine requires the development of a multi-pronged strategy addressing all

aspects in relation to acceptability (e.g. the motivation to immunize despite the

quasi-disappearance of the disease), accessibility (e.g. supply chain services),

availability (e.g. mechanisms ensuring reliability of supply) and affordability

(e.g. tiered pricing policy taking country differences in per capita income into

account). Leveraging novel technological advances can positively influence

the ability to activate these levers successfully.

Biography

Pierre A Morgon is the CEO of MRGN Advisors

and regional partner for Switzerland at Mérieux

Développement. He served as a Chairman of

the Board of Virometix, as well as Non-Executive

Director to the Boards of Theradiag, of Eurocine

Vaccines, of Alma Biotherapeutics and of Vacci-

tech. He has over 30 years of experience in the

global life science industry, especially with vac-

cines and immunotherapy, at the helm of inter-

national operations, in C-level positions at glob-

al level and as CEO of start-ups. He works as a

Lecturer in several MBA programs in world-class

business schools and in life science conferences,

as well as to the Mass Challenge Biotechnology

incubator in Switzerland. He holds a Doctor of

Pharmacy, a master’s in Business Law and an

MBA. He is also an alumnus of INSEAD and IMD.

pm@mrgna

visors.com

NOVEL TECHNOLOGIES CAN

SUCCESSFULLY ACTIVATE POSITIVE

BEHAVIORS OF STAKEHOLDERS

INVOLVED IN VACCINE PURCHASING

AND USAGE

Pierre A Morgon

MRGN Advisors, Switzerland

Pierre A Morgon, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-002